Eohilia denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues an Experimental Denial for Eohilia in Eosinophilic Esophagitis

An experimental or investigational denial for Eohilia is almost always a classification error or policy-lag issue. Eohilia (budesonide oral suspension) received FDA approval specifically for eosinophilic esophagitis (EoE) in adults and adolescents meeting the criteria in the prescribing label. When Aetna's clinical policy has not yet been updated to reflect a relatively new FDA approval, or when the claim is filed for a patient whose age or presentation does not match an approved pathway in Aetna's internal system, the automated review may flag the drug as experimental even though it carries full FDA approval for the submitted indication.

## Why This Denial Is Appealable

FDA approval is the established legal standard for distinguishing approved treatment from experimental use. A plan that denies an FDA-approved drug for its approved indication as "experimental" is making an error of fact that can be directly rebutted with the label. Under ACA §2719, non-grandfathered plans are required to offer internal appeal and independent external review. Under ERISA §503, employer-plan members are entitled to a full-and-fair review with a written, reasoned explanation. The internal appeal window is typically 180 days from the denial date. External review must generally be requested within 4 months of a final internal denial. Expedited review is available when delay poses a serious health risk.

## Concrete Appeal Steps

1. Obtain the FDA-approved label: Download the current prescribing information for Eohilia from the FDA's Drugs@FDA database. Identify and highlight the eosinophilic esophagitis indication section. 2. Request Aetna's experimental/investigational criteria: Aetna's policy documents must disclose the standard it applied. Read each criterion carefully. 3. File an internal appeal enclosing the FDA label and a cover letter noting that the denial premise is factually incorrect for the stated indication. 4. Reference professional society guidance: The applicable ACG (American College of Gastroenterology) or AGA (American Gastroenterological Association) clinical guideline for EoE recognizes swallowed topical corticosteroids as standard-of-care treatment — cite the organization without quoting statistics. 5. Request external review if the internal appeal is denied — an independent reviewer is required to recognize FDA approval as the controlling standard.

## Documentation to Gather

• FDA label for Eohilia: current full prescribing information confirming the EoE indication and the patient population covered.
• EoE diagnosis records: endoscopy reports with biopsy results confirming the diagnosis, hematology and eosinophil count documentation, and gastroenterology evaluation notes.
• Prescriber attestation letter: a letter from the treating gastroenterologist confirming that the prescription is for the FDA-approved indication of EoE, that the use is standard of care per relevant GI society guidelines, and that the treatment is not experimental.
• Guideline reference: a citation to the applicable ACG or AGA clinical guideline for EoE acknowledging swallowed topical corticosteroids as an established treatment option.

## Criteria-Mapping Structure

| Aetna Experimental Criterion | Rebuttal Evidence | |---|---| | Drug lacks FDA approval for stated indication | Eohilia FDA label — EoE indication section (attached) | | Use not recognized as standard of care | ACG/AGA guideline citation confirming standard-of-care status | | Patient does not meet on-label criteria | Diagnosis records + prescriber attestation matching label population |

Always use the most current version of the FDA-approved prescribing information for Eohilia and Aetna's clinical policy for EoE treatments to anchor every element of your rebuttal to documented, verifiable facts.